Money Concepts Capital Corp Sells 4,126 Shares of Gilead Sciences, Inc. $GILD

Money Concepts Capital Corp lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.6% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 86,105 shares of the biopharmaceutical company’s stock after selling 4,126 shares during the period. Gilead Sciences accounts for 0.6% of Money Concepts Capital Corp’s holdings, making the stock its 29th biggest position. Money Concepts Capital Corp’s holdings in Gilead Sciences were worth $10,568,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Bailard Inc. raised its stake in shares of Gilead Sciences by 9.7% during the 4th quarter. Bailard Inc. now owns 734,057 shares of the biopharmaceutical company’s stock worth $90,098,000 after purchasing an additional 65,056 shares in the last quarter. Trek Financial LLC raised its stake in shares of Gilead Sciences by 510.8% during the 4th quarter. Trek Financial LLC now owns 15,594 shares of the biopharmaceutical company’s stock worth $1,914,000 after purchasing an additional 13,041 shares in the last quarter. AG2R LA Mondiale Gestion D Actifs raised its stake in shares of Gilead Sciences by 5.6% during the 4th quarter. AG2R LA Mondiale Gestion D Actifs now owns 49,784 shares of the biopharmaceutical company’s stock worth $6,110,000 after purchasing an additional 2,652 shares in the last quarter. Certior Financial Group LLC raised its stake in shares of Gilead Sciences by 6.9% during the 4th quarter. Certior Financial Group LLC now owns 3,894 shares of the biopharmaceutical company’s stock worth $478,000 after purchasing an additional 250 shares in the last quarter. Finally, Centric Wealth Management raised its stake in shares of Gilead Sciences by 5.4% during the 4th quarter. Centric Wealth Management now owns 27,085 shares of the biopharmaceutical company’s stock worth $3,324,000 after purchasing an additional 1,384 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead delivered Q1 revenue of $6.96 billion, up 4.4% year over year and ahead of expectations, while adjusted EPS of $2.03 also beat consensus. Management said full-year revenue should come in around $30.2 billion, roughly in line with Wall Street estimates, which supports the view that core operations remain stable. Article: GILD Q1 Deep Dive: HIV Growth, Oncology Pipeline, and Margin Management Shape 2026 Outlook
• Positive Sentiment: Analysts continue to see upside from Gilead’s HIV business and oncology pipeline, and Truist recently reiterated a Buy rating, which can help reinforce investor confidence in the stock. Article: Gilead Sciences Earns Buy Rating from Truist Financial
• Neutral Sentiment: Several firms have updated valuation models after the earnings release, including Rothschild & Co Redburn trimming its price target to $167 and RBC lowering its target to $122, reflecting a mixed analyst reaction rather than a clear shift in the long-term thesis. Article: Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences to $167 from $170
• Negative Sentiment: The biggest concern is Gilead’s sharply reduced fiscal 2026 EPS outlook, which now calls for a loss of $1.05 to $0.65 per share after accounting for about $11.5 billion in IPR&D and financing costs. That guidance cut is likely the main reason shares are facing pressure despite the earnings beat. Article: Gilead Sciences, Inc. (GILD) Outlook Cut Sharply on $11.5B IPR&D and Financing Costs

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the company. Truist Financial reissued a “buy” rating and set a $157.00 target price (up from $155.00) on shares of Gilead Sciences in a report on Friday. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “hold” rating in a report on Saturday. Oppenheimer boosted their target price on Gilead Sciences from $128.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, February 11th. Finally, Cantor Fitzgerald decreased their target price on Gilead Sciences from $155.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, April 10th. Twenty-four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $157.04.

Gilead Sciences Stock Performance

Shares of NASDAQ GILD opened at $133.52 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.97 and a quick ratio of 1.77. The stock’s fifty day moving average price is $139.07 and its two-hundred day moving average price is $132.99. Gilead Sciences, Inc. has a one year low of $96.18 and a one year high of $157.29. The firm has a market cap of $165.77 billion, a price-to-earnings ratio of 18.19 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, beating analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a return on equity of 48.19% and a net margin of 30.99%.The firm had revenue of $6.96 billion for the quarter, compared to analyst estimates of $6.91 billion. During the same period in the prior year, the firm posted $1.81 EPS. The company’s revenue for the quarter was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.85 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 29th. Shareholders of record on Monday, June 15th will be issued a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio is currently 44.69%.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Tuesday, April 28th. The stock was sold at an average price of $129.16, for a total transaction of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. This represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total value of $463,290.00. Following the sale, the chief financial officer owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 63,000 shares of company stock valued at $9,238,250 in the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.